Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive BetSeeking Alpha • 02/12/22
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022GlobeNewsWire • 02/10/22
GSK, Vir Say Their Covid Antibody Treatment Can Neutralize Fast-Spreading Omicron RelativeForbes • 02/10/22
Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2GlobeNewsWire • 02/10/22
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 157%: Here's is How to TradeZacks Investment Research • 02/08/22
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, GlobalGlobeNewsWire • 02/08/22
Vir, GSK ask FDA to update EUA for their monoclonal antibody to include intramuscular administrationMarket Watch • 01/13/22
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of MalariaGlobeNewsWire • 01/13/22
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19GlobeNewsWire • 01/13/22
Vir Biotechnology, Inc. (VIR) Soars 15.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/13/22
Vir Biotechnology, Inc. (VIR) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 01/12/22
GlaxoSmithKline, Vir shares up as U.S. orders more doses of COVID treatment sotrovimabMarket Watch • 01/11/22
GlaxoSmithKline to ship 600,000 more doses of COVID treatment sotrovimab to U.S.Market Watch • 01/11/22